Watson stock up on recertification
From Times Wire Services
Shares of Watson Pharmaceuticals Inc., the second-largest U.S. maker of generic drugs, gained the most in almost a year after the Corona-based company’s Florida plant was cleared to make new products for the first time since 2005.
The recertification by the Food and Drug Administration removes hurdles for long-delayed products including copies of AstraZeneca’s antacid Prilosec and blood-pressure medicine Toprol XL.
Watson shares rose $2, or 6.9%, to $31.14.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
